Delivery Order 36F79718D0566-36C26124N0658
Award Date
5/16/24
Potential Completion Date
5/30/24
Potential Value
$22K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Biogen U.s. Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm-fixed-price delivery order to Biogen U.S. Corporation, a pharmaceutical manufacturer, for the supply of QALSODY and QALSODY (TOFERSEN) 6.7MG SOLN. This $43,476.60 order was placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract and will be delivered by June 1, 2024. Biogen also holds a $11.39 million single-award indefinite delivery contract with the VA National Acquisition Center to provide...
This contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Biogen U.S. Corporation, a biotechnology company focused on developing therapies for neurological diseases. It is a delivery order against Biogen's Pharmaceuticals and Drugs GSA Schedule contract, with a firm-fixed-price of $10,869.15. The contract is for the pharmaceutical product QALSODY (TOFERSEN), which is likely used to treat neurological conditions in veterans. This order was placed by...
This federal contract award, valued at $43,476.60, was issued by the Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is a firm-fixed-price delivery order placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract. The contract is for the delivery of QALSODY (tofersen), a pharmaceutical product used to treat neurological conditions in veterans. This award does not carry a...
This federal contract award to Biogen U.S. Corporation is for the delivery of the pharmaceutical product QALSODY (tofersen) to the U.S. Department of Veterans Affairs (VA). The $21,738.30 firm fixed price delivery order is placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract. The contract has no set-aside designation, indicating Biogen competed against other vendors to secure this award. Biogen U.S. Corporation is a subsidiary of Biogen Idec Incorporated that focuses on...
This federal contract award is a firm fixed-price delivery order issued by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract, valued at $485,835.00, is for the supply of DALFAMPRIDINE 100 MG, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract was awarded on January 17, 2017, with a final completion date of...
This is a firm fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies. The $861,948.00 contract is for the supply of DALFAMPRIDINE, a medication used to treat Parkinson's disease symptoms. The contract is placed under Acorda's Federal Supply Schedule (FSS) contract with the VA, which is valued at over $16.3 million and allows the VA to procure Acorda's pharmaceutical...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Grifols Therapeutics LLC, a for-profit manufacturer and supplier of pharmaceuticals and biopharmaceuticals. The $136,024.56 delivery order was issued under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) and has a firm fixed price. The order is for the VA's Veterans Integrated Service Network 19 to procure pharmaceutical products, with a period of performance through September 30,...
This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21 (VISN 21) to Genzyme Corporation, doing business as Sanofi Genzyme, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The $89,094.00 order is for the delivery of various specialty pharmaceutical products, including Eliglustat (Cerdelga), Lemtrada, and Caprelsa (vandetanib), to support treatment programs for veterans. Genzyme...
The Department of Veterans Affairs Veterans Health Administration awarded a $652,376 delivery order to Neurocrine Biosciences, Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The order calls for the delivery of VALBENAZINE 80MG capsules to the Hines VA Medical Center in Illinois. The one-week period of performance from November 3 to November 10, 2020 indicates this was likely an urgent order to treat veterans for a condition addressed by the medication. Neurocrine...
This is a firm fixed-price delivery order awarded to CSL Behring L.L.C., a foreign-owned, for-profit biotherapeutics company, by the U.S. Department of Veterans Affairs (VA). The contract is part of the VA's Federal Supply Schedule (FSS) for Pharmaceuticals and Drugs (FSS-61-IB), with a ceiling value of $75,295.97. The order is for pharmaceutical products, including medications like HAEGARDA, Privigen, Hizentra, and Kcentra, to support healthcare services for veterans across different VA medical...